Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

The nonclinical pharmacokinetic (PK) and pharmacodynamic (PD) study was conducted to examine the effects of semaglutide ...

Novo Nordisk's work goes beyond diabetes and obesity, which are currently its core areas. The drugmaker has been looking to diversify its lineup for years. For one, semaglutide, the active ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share ...